Sugi Predict

Sugi Predict / Compounds / SCHEMBL2344585

SCHEMBL2344585

SCHEMBL2344585

O=C(O)c1ccc(-c2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 4/20 0.72
▸ RXRB P28702 4/20 0.72
▸ RXRG P48443 3/20 0.72
▸ SRD5A2 P31213 2/20 0.66
▸ MEN1 O00255 2/20 0.63
▸ KMT2A Q03164 2/20 0.63
▸ KDM4E B2RXH2 1/20 0.63
▸ ALDH1A1 P00352 1/20 0.63
▸ KIF11 P52732 1/20 0.59
▸ DHODH Q02127 1/20 0.58
▸ IP6K1 Q92551 1/20 0.56
▸ IP6K3 Q96PC2 1/20 0.56
▸ IP6K2 Q9UHH9 1/20 0.56
▸ NR4A2 P43354 1/20 0.55
▸ NPC1 O15118 1/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ CFTR P13569 1/20 0.54
▸ TRIM24 O15164 1/20 0.54
▸ TRIM33 Q9UPN9 1/20 0.54
▸ PLG P00747 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29784281 1.00 RXRA (0.72) RXRARXRBRXRGSRD5A2MEN1
SCHEMBL30393660 0.88 RXRA (0.63) RXRARXRBRXRGSRD5A2MEN1
SCHEMBL177461 0.88 RXRA (0.63) RXRARXRBRXRGSRD5A2MEN1
SCHEMBL4618676 0.86 SRD5A2 (0.70) RXRARXRBRXRGSRD5A2MEN1
SCHEMBL2984165 0.85 KIF11 (0.58) RXRARXRBRXRGMEN1KMT2A
SCHEMBL30469525 0.85 DHODH (0.61) RXRARXRBRXRGSRD5A2MEN1
SCHEMBL25560577 0.85 DHODH (0.61) RXRARXRBRXRGSRD5A2MEN1
SCHEMBL14149921 0.84 NPC1 (0.62) RXRARXRBRXRGMEN1KMT2A
SCHEMBL23698041 0.84 RXRA (1.00) RXRARXRBRXRGSRD5A2DHODH
SCHEMBL24106776 0.83 KIF11 (0.67) ALDH1A1KIF11PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 — — US claimed
US-7368462-B1 Melanin concentrating hormone antagonists THE PROCTER & GAMBLE COMPANY (US) 2008-05-06 — — US claimed
US-7304065-B2 Melanin concentrating hormone antagonists THE PROCTER & GAMBLE COMPANY (US) 2007-12-04 — — US claimed
US-20050075324-A1 Melanin concentrating hormone antagonists THE PROCTER & GAMBLE COMPANY (US) 2005-04-07 — — US claimed
US-12240827-B2 Serotonin 5-HT2B inhibitory compounds ZOETIS SERVICES LLC (US) 2025-03-04 — — US disclosed
EP-3947360-B1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS ZOETIS SERVICES LLC (US) 2024-08-07 — — EP disclosed
CN-113631548-B Serotonin 5-HT2B inhibiting compounds 硕腾服务有限责任公司 2023-06-06 — — CN disclosed
US-11390610-B2 Piperazine derivatives as MAGL inhibitors HOFFMANN-LA ROCHE INC. (US) 2022-07-19 — — US disclosed
US-20220184041-A1 (AZA)Benzothiazolyl Substituted Pyrazole Compounds PFIZER INC. (US) 2022-06-16 — — US disclosed
WO-2022112919-A1 (AZA)BENZOTHIAZOLYL SUBSTITUTED PYRAZOLE COMPOUNDS PFIZER INC. (US) 2022-06-02 — — WO disclosed
US-20220162183-A1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS ZOETIS SERVICES LLC 2022-05-26 — — US disclosed
EP-3694840-B1 PIPERAZINE DERIVATIVES AS MAGL INHIBITORS HOFFMANN LA ROCHE (CH) 2021-08-04 — — EP disclosed
US-20030212012-A1 Pharmaceutically active pyrrolidine derivatives MERCK SERONO SA (CH) 2003-11-13 — — US disclosed
US-20030171309-A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors MERCK SERONO SA (CH) 2003-09-11 — — US disclosed
EP-1268418-A1 PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS Applied Research Systems ARS Holding N.V. (AN) 2003-01-02 — — EP disclosed
EP-1268419-A1 PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS Applied Research Systems ARS Holding N.V. (AN) 2003-01-02 — — EP disclosed
WO-2002074741-A1 PYRROLIDINE ESTER DERIVATIVES WITH OXYTOCIN MODULATING ACITVITY APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) 2002-09-26 — — WO disclosed
WO-2001074769-A1 PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-10-11 — — WO disclosed
WO-2001072705-A1 PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-10-04 — — WO disclosed
EP-0341514-A2 Process for the preparation of asymmetrical biaryle compounds BAYER AG (DE) 1989-11-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212012-A1 Pharmaceutically active pyrrolidine derivatives OXTR, CNR1, PRLHR RXRA 1044/4885RXRB 934/4885RXRG 975/4885
US-12240827-B2 Serotonin 5-HT2B inhibitory compounds HTR2B, HTR1B, HTR5A RXRA 3714/4885RXRB 2415/4885RXRG 3723/4885
US-20220162183-A1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS HTR2B, HTR1B, HTR5A RXRA 3714/4885RXRB 2415/4885RXRG 3723/4885
US-20050075324-A1 Melanin concentrating hormone antagonists MCHR1, MCHR2, MC1R RXRA 1395/4885RXRB 1565/4885RXRG 1073/4885
US-11390610-B2 Piperazine derivatives as MAGL inhibitors MAGI3, PYM1, MAG RXRA 4515/4885RXRB 4498/4885RXRG 4575/4885
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 RXRA 378/4885RXRB 394/4885RXRG 384/4885
US-20220184041-A1 (AZA)Benzothiazolyl Substituted Pyrazole Compounds TTR, APOB, SERPINB6 RXRA 715/4885RXRB 503/4885RXRG 1681/4885
US-20030171309-A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors SUCNR1, PYCR1, GLS RXRA 1208/4885RXRB 842/4885RXRG 1092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.